Cargando…

Highlights: burden of venous thromboembolism and role of extended-duration thromboprophylaxis in acute medically ill patients

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016711/ https://www.ncbi.nlm.nih.gov/pubmed/29977162 http://dx.doi.org/10.1093/eurheartj/suy018

Ejemplares similares

Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis
por: Ageno, Walter, et al.
Publicado: (2018)

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals
por: Martin, Anne-Céline, et al.
Publicado: (2019)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis
por: Coleman, Craig I., et al.
Publicado: (2020)

New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients
por: MacDougall, Kira, et al.
Publicado: (2020)

Thromboprophylaxis for venous thromboembolism prevention in hip fracture patients
Publicado: (2017)

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
por: Cohen, Alexander T
Publicado: (2018)

Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis
por: Minet, Clémence, et al.
Publicado: (2015)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis
por: Huang, Jimmy, et al.
Publicado: (2022)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care
por: Willems, R. A. L., et al.
Publicado: (2023)

High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
por: Hamada, S. R., et al.
Publicado: (2017)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Does thromboprophylaxis prevent venous thromboembolism after major orthopedic surgery?,
por: Akpinar, Evrim Eylem, et al.
Publicado: (2013)

Betrixaban for prevention of venous thromboembolism in acute medically ill patients
por: Beyer-Westendorf, Jan, et al.
Publicado: (2018)

Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis
por: Miao, Benjamin, et al.
Publicado: (2019)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery
por: Gao, Yuan, et al.
Publicado: (2016)

Awareness of venous thromboembolism and thromboprophylaxis among hospitalized patients: a cross-sectional study
por: Almodaimegh, Hind, et al.
Publicado: (2017)

Venous Thromboembolism Among Hospitalized Patients: Incidence and Adequacy of Thromboprophylaxis – A Retrospective Study
por: Ambra, Naseem, et al.
Publicado: (2022)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis
por: Zhang, Cong, et al.
Publicado: (2020)

Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment
por: Aryal, Madan Raj, et al.
Publicado: (2020)

An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients
por: Samama, Meyer Michel, et al.
Publicado: (2006)

Post-hepatectomy venous thromboembolism: a systematic review with meta-analysis exploring the role of pharmacological thromboprophylaxis
por: Karunakaran, Monish, et al.
Publicado: (2022)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Venous Thromboembolism Risk and Thromboprophylaxis Assessment in Surgical Patients Based on Caprini Risk Assessment Model
por: Tadesse, Tamrat Assefa, et al.
Publicado: (2020)

Challenges of extended venous thromboembolism prophylaxis in medical and surgical patients
por: Chindamo, Maria Chiara, et al.
Publicado: (2022)

Analysis of Adherence to Thromboprophylaxis and Incidence of Venous Thromboembolism After Lower Limb Orthopaedic Surgery
por: Benjamin, Miles W, et al.
Publicado: (2021)

Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study
por: Forté, Stéphanie, et al.
Publicado: (2022)

Is thromboprophylaxis effective in reducing the pulmonary thromboembolism?
por: Rajabi, Fereshteh, et al.
Publicado: (2012)

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors
por: Artifoni, Mathieu, et al.
Publicado: (2020)

Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA
por: Amin, Alpesh, et al.
Publicado: (2019)

Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment
por: Al Yami, Majed S, et al.
Publicado: (2018)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction
por: Pittelkow, Eric M., et al.
Publicado: (2021)

Limitations of venous thromboembolism risk assessment models in medical patients: Response to “Unmet definitions in thromboprophylaxis for hospitalized medical patients: An appraisal for the need of recommendation”
por: Er, Chaozer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h3kkdj8s4cmq2iv2q1ighsrl9j